✦ LIBER ✦

Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway

✍ Scribed by Bernd Moosmann; Christian Behl

Book ID: 113926881
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 307 KB
Volume: 14
Category: Article
ISSN: 1050-1738
DOI: 10.1016/j.tcm.2004.08.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The combined use of cholesterol-lowering

The combined use of cholesterol-lowering drugs and cholesterol-lowering bread spreads: health behavior data from Finland

✍ Nynke de Jong; Meri Simojoki; Tiina Laatikainen; Heli Tapanainen; Liisa Valsta; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Role of cholesterol-enriched diet and th

Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis

✍ Zoltán Giricz; Csaba Csonka; Annamária Ónody; Tamás Csont; Péter Ferdinandy 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 122 KB

Chemotaxis of the monocyte cell line U93

Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products

✍ Jörg Kreuzer; Jörg Bader; Lothar Jahn; Martina Hautmann; Wolfgang Kübler; Eberha 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 719 KB

The Ebbs and Flows in the Development of

The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future

✍ Hajhosseiny, R; Sabir, I; Khavandi, K; Wierzbicki, A S 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 555 KB

The phenomenon of regression to the mean

The phenomenon of regression to the mean and clinical investigation of blood cholesterol lowering drugs

✍ J. P. Boissel; B. Duperat; A. Leizorovicz 📂 Article 📅 1980 🏛 Springer 🌐 English ⚖ 458 KB

The role of diet and drugs in lowering s

The role of diet and drugs in lowering serum cholesterol in the postmyocardial infarction patient

✍ G. Schettler 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 447 KB

Lipid disorders are the most important factors in the development of coronary heart disease (CHD). They need to be treated in primary as well as in secondary prevention. U.S. and European Consensus Conferences agreed that desirable serum cholesterol levels should not exceed 200 mg/dL. When baseline